Eurocirce, una Organizzazione di Produttori dal 1979
For a Part D rebatable drug first approved or licensed on or before October 1, 2021, section 1860D-14B(b)(4) of the Act specifies that the benchmark period manufacturer price is the sum of the products of (1) the AMP for the Part D rebatable drug reported for each calendar quarter of the payment amount benchmark period (that is, January 1, 2021, through September 30, 2021), and (2) the total units reported for each of the corresponding calendar quarters of the payment amount benchmark period divided by the total units of the Part D rebatable drug reported for the 3 calendar quarters in the payment amount benchmark period
More specifically, we were only able to determine that the increase in billing on HCPCS codes A4352 and A4353 in CY 2023 represented SAHS billing activity after the calendar year ended
To codify the existing process for multiple data submissions for the quality and improvement activities performance categories, we are proposing to add at 414.1325(f)(1) that for multiple data submissions received in the quality and improvement activities performance categories in accordance with paragraphs (a)(1)(i) and (ii) for an individual MIPS eligible clinician, group, subgroup, or virtual group from submitters in multiple organizations (for example, qualified registry, practice administrator, or EHR vendor), CMS will calculate and score each submission received and assign the highest of the scores
